度普利尤单抗治疗5例难治性内源性角化型手足部湿疹

doi:10.35541/cjd.20230429

Abstract

Abstract: 【Abstract】 Endogenous hyperkeratotic hand eczema, as a chronic inflammatory disease, is difficult to be cured, and to be controlled by traditional therapies. In this article, dupilumab was used in 5 patients with endogenous hyperkeratotic hand （foot） eczema, who exhibited poor response to traditional therapies. The results showed that dupilumab could rapidly improve skin lesions and relieve itching, with high safety and marked efficacy.

Key words: Biological agents, Eczema, Dupilumab, Endogenous hyperkeratotic hand eczema

Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema[J]. Chinese Journal of Dermatology,2024,e20230429. doi:10.35541/cjd.20230429

References ［14］

［1］	Menné T, Johansen JD, Sommerlund M, et al. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema［J］. Contact Dermatitis, 2011,65（1）:3⁃12. doi: 10.1111/j.1600⁃0536.2011.01915.x.
［2］	中国医师协会皮肤科医师分会科学委员会中国医师协会皮肤科医师分会变态反应性疾病专业委员会中国“手部湿疹科研协作组”. 中国手部湿疹诊疗专家共识（2021版）［J］. 中华皮肤科杂志, 2021,54（1）:19⁃26. doi:10.35541/cjd.20200281.
［3］	Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention［J］. J Eur Acad Dermatol Venereol, 2020,34 Suppl 1:4⁃12. doi: 10.1111/jdv.16061.
［4］	Held E, Skoet R, Johansen JD, et al. The hand eczema severity index （HECSI）: a scoring system for clinical assessment of hand eczema. A study of inter⁃ and intraobserver reliability［J］. Br J Dermatol, 2005,152（2）:302⁃307. doi: 10.1111/j.1365⁃2133.2004. 06305.x.
［5］	Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis ⁃ a systematic review［J］. J Dermatolog Treat, 2021,32（1）:19⁃28. doi: 10.1080/09546634.2019.1689227.
［6］	Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema⁃⁃short version［J］. J Dtsch Dermatol Ges, 2015,13（1）:77⁃85. doi: 10. 1111/ddg.12510.
［7］	Dubin C, Del Duca E, Guttman⁃Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges［J］. Ther Clin Risk Manag, 2020,16:1319⁃1332. doi: 10.2147/TCRM.S292504.
［8］	Voorberg AN, Romeijn G, de Bruin⁃Weller MS, et al. The long⁃term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis⁃52 week results from the Dutch BioDay Registry［J］. Contact Dermatitis, 2022,87（2）:185⁃191. doi: 10.1111/cod.14104.
［9］	Zhu GA, Honari G, Ko JM, et al. Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: a case report［J］. JAAD Case Rep, 2020,6（4）:296⁃298. doi: 10.1016/j.jdcr. 2020.02.010.
［10］	Loman L, Diercks G, Schuttelaar M. Three cases of non⁃atopic hyperkeratotic hand eczema treated with dupilumab［J］. Contact Dermatitis, 2021,84（2）:124⁃127. doi: 10.1111/cod.13693.
［11］	Li Y, Xiao J, Sun Y, et al. Quick treatment of very severe refractory hand and foot eczema with dupilumab: a case report and literature review［J］. J Asthma Allergy, 2023,16:1⁃8. doi: 10.2147/JAA.S399340.
［12］	Li T, Li H, Zhang J. Dupilumab use in non⁃atopic chronic hand eczema: two cases and a review of the literature［J］. Indian J Dermatol Venereol Leprol, 2023:1⁃3. doi: 10.25259/IJDVL_721_2022.
［13］	Politiek K, Loman L, Pas HH, et al. Hyperkeratotic hand eczema: eczema or not?［J］. Contact Dermatitis, 2020,83（3）:196⁃205. doi: 10.1111/cod.13572.
［14］	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 度普利尤单抗治疗特应性皮炎专家共识［J］. 中华皮肤科杂志, 2022,55（6）:465⁃470. doi:10. 35541/cjd.20210885.

[1]	Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378.
[2]	Li Yuanjun, Han Yuyang, Zhang Huanzhen, Wang Hui, Shen Nan, Zhang Xinglian. Dupilumab in the treatment of 12 children with chronic spontaneous urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(3): 254-257.
[3]	Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578.
[4]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 0(2): 20230006-e20230006.
[5]	China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.
[6]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[7]	Wei Jin, Yan Huiwen, Zhao Tianwei, Ran Liwei, Lun Wenhui, Zhang Jianzhong. Eczematoid clear cell acanthoma of the nipple/areola: the first case reported in China and literature analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 545-548.
[8]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[9]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[10]	Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Committee on Dermatology, Chinese Association of Geriatric Research, Committee on Dermatological Drug Research, The Chinese Association of Traditional Chinese Medicine. Expert consensus on integrated traditional Chinese and Western medicine for eczema and dermatitis [J]. Chinese Journal of Dermatology, 2023, 56(4): 287-293.
[11]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[12]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[13]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[14]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[15]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.

Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［14］

Related Articles 15

Metrics

Comments

Recommended 10